Technical Analysis for CERO - CERo Therapeutics Holdings, Inc.

Grade Last Price % Change Price Change
C 0.25 -3.60% -0.01
CERO closed down 3.6 percent on Wednesday, November 20, 2024, on 17 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Calm After Storm Range Contraction -3.60%
Wide Bands Range Expansion -3.60%
Calm After Storm Range Contraction 3.80%
Wide Bands Range Expansion 3.80%
Gapped Down Weakness 3.80%
Gilligan's Island Sell Setup Bearish Swing Setup -12.79%

   Recent Intraday Alerts

Alert Time
Gapped Down (Partial) about 21 hours ago
Down 5% about 21 hours ago
Down 3% about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CERo Therapeutics Holdings, Inc. Description

CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.


Classification

Sector: Other
Industry: Other
Keywords: Cancer Solid Tumors Immune System Immunotherapy Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Lymphoma Virotherapy Hematological Malignancies Adoptive Cell Transfer T Cells Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Therapy Car T Cell Treating Cancer

Is CERO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.8
52 Week Low 0.0636
Average Volume 80,225,037
200-Day Moving Average 1.78
50-Day Moving Average 0.11
20-Day Moving Average 0.14
10-Day Moving Average 0.20
Average True Range 0.05
RSI (14) 64.66
ADX 44.77
+DI 53.59
-DI 13.25
Chandelier Exit (Long, 3 ATRs) 0.29
Chandelier Exit (Short, 3 ATRs) 0.22
Upper Bollinger Bands 0.30
Lower Bollinger Band -0.02
Percent B (%b) 0.83
BandWidth 229.32
MACD Line 0.04
MACD Signal Line 0.03
MACD Histogram 0.0162
Fundamentals Value
Market Cap 1.55 Million
Num Shares 6.23 Million
EPS -0.35
Price-to-Earnings (P/E) Ratio -0.71
Price-to-Sales 0.00
Price-to-Book 123.73
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.32
Resistance 3 (R3) 0.32 0.30 0.31
Resistance 2 (R2) 0.30 0.28 0.30 0.30
Resistance 1 (R1) 0.27 0.27 0.29 0.27 0.30
Pivot Point 0.25 0.25 0.26 0.25 0.25
Support 1 (S1) 0.23 0.23 0.24 0.23 0.20
Support 2 (S2) 0.21 0.22 0.20 0.20
Support 3 (S3) 0.18 0.21 0.19
Support 4 (S4) 0.18